MOST UP TO DATE INFO I HAVE ON ACAM-529, UPDATE CAME FROM WIKIPEDIA: A laboratory at Harvard Medical School has developed dl5-29 (now known as ACAM-529), a replication-defective mutant virus that has proved successful both in preventing HSV-2/HSV-1 infections, and in combating the virus in already infected hosts, in animal models. It has been shown that the replication-defective vaccine induces strong HSV-2-specific antibody and T-cell responses; protects against challenge with a wild-type HSV-2 virus; greatly reduces the severity of recurrent disease; provides cross-protection against HSV-1, and renders the virus unable to revert to a virulent state or to become latent. His vaccine is now being researched and developed by Accambis (acquired by Sanofi Pasteur in September 200, and is due to be applied as an Investigational New Drug in 2009. However, the status of ACAM-529 became after the acquisition somewhat unclear. According to Jim Tartaglia, a company representative of Sanofi Pasteur, ACAM-529 is still under development and should be enter phase I clinical testing in 2012. Now I can understand why Sanofi-Pasteur was so eager to snatch it up.